Table 1 Characteristics of the included studies.
From: Efficacy and safety of macrolides in the treatment of children with bronchiectasis: a meta-analysis
Author, year | Location | Study design | Sample size, total (T/C) (F/M) | Age (T/C) (year, mean or median) | Diagnosis | Exacerbation history and bronchiectasis states | Macrolide dose and frequency | Comparison | Therapy duration follow-up |
|---|---|---|---|---|---|---|---|---|---|
Goyal, 2018 | Australia, New Zealand | DB-RCT | 179 (82/97) (84/95) | 6.4 (4.0–9.0)/6.8 (4.3–10.1) | Clinical features and HRCT | Stable bronchiectasis, ≥2 exacerbations in the previous 18 months | Azithromycin (5 mg/kg per day)/amoxicillin-clavulanate (22.5 mg/kg twice daily) | Placebo | 3 weeks 6 months |
Goyal, 2019 | Australia, New Zealand | DB-RCT | 197 (67/63/67) (93/104) | 6.0(3.6–9.5)/6.0(3.7–8.6) | CT | Stable bronchiectasis, ≥2 exacerbations in the previous 18 months | Azithromycin (5 mg/kg per day (maximum 200 mg) as a once daily dose)/amoxicillin-clavulanate (45 mg/kg per day (maximum 880 mg), divided into twice daily doses) | Placebo (amoxicillin-clavulanate or azithromycin) | 2 weeks 6 months |
Hare, 2015 | Australia, New Zealand | DB-RCT | 78 (41/37) (37/41) | 4.2 (1.4–8.9)/5.4 (1.8–9.0) | Clinical features or HRCT | Stable bronchiectasis, ≥1 exacerbation in the past year | Azithromycin (30 mg/kg, once weekly) | Placebo | 24 months |
Koh, 1997 | Korea | DB-RCT | 25 (13/12) (11/14) | 10–18 | Clinical features and CT | Stable bronchiectasis, increased AR | Roxithromycin 4 mg/kg twice daily | Placebo | 12 weeks 12 weeks |
Masekela, 2013 | South Africa | DB-RCT | 31 (17/14) (13/18) | 6–18 | HRCT | Bronchiectasis associated with HIV | Erythromycin, <15 kg 125 mg, >15 kg 250 mg per day | Placebo | 52 weeks 52 weeks |
Valery, 2013 | Australia | DB-RCT | 89 (45/44) (47/42) | 1–8 | HRCT | Stable bronchiectasis, ≥1 exacerbation in the past year | Azithromycin 30 mg/kg once a week | Placebo | 12–24 months 12–24 months |
Yalçin, 2006 | Turkey | RCT | 34 (17/17) (15/19) | 13.1 ± 2.7/11.9 ± 2.9 | Clinical features and HRCT | Clinically stable with no evidence of acute pulmonary exacerbation | Clarithromycin,15 mg/kg, daily | Supportive therapies (no intervention) | 3 months |
